SFI
GLMD icon

Susquehanna Fundamental Investments’s Galmed Pharmaceuticals GLMD Stock Holding History

Susquehanna Fundamental Investments’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-57
Closed -$31K – 1771
2021
Q2 		$31K Sell
57
-9
-14% -$4.89K ﹤0.01% 1636
2021
Q1 		$41K Buy
+66
New +$45.7K ﹤0.01% 1504

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna Fundamental Investments's GLMD Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Galmed Pharmaceuticals (GLMD) in Q3 2021, closing a stake of 57 shares — an estimated $31K sold.

Susquehanna Fundamental Investments first reported a position in GLMD in Q1 2021 and held it in 2 quarters. The position peaked at $41K in Q1 2021. 26 funds tracked by Wall St. Rank hold GLMD as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining Galmed Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 57 Galmed Pharmaceuticals shares in Q3 2021, an estimated $31K.
  • Susquehanna Fundamental Investments first reported a position in Galmed Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Galmed Pharmaceuticals position peaked at $41K in Q1 2021.
  • 26 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.